Author/Authors :
Khoonsari، Hasan نويسنده Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran , , Oghazian، Mohammad Bagher نويسنده Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran , , Kargar، Mona نويسنده Research Center for Rational Use of Drugs, Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran , , Moin، Mahdiyeh نويسنده Department of Psychiatry, Roozbeh Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran , , Khalili، Hossein نويسنده , , Alimadadi، Abbas نويسنده Psychiatry and psychology Research center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran , , Torkamandi، Hassan نويسنده Department of Pharmaceutical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Torkamandi, Hassan , Ghaeli، Padideh نويسنده PharmD, Psychiatric Research Center, Roozbeh Psychiatric Hospital, TUMS, Tehran ,
Abstract :
Background: Patients with mixed anxiety-depressive disorder (MADD) suffer both anxiety and depression. Antidepressants, especially, selective serotonin reuptake inhibitors are among agents of choice for treating this condition.
Objectives: This study compared the efficacy of Cipram® with its generic, citalopram.
Patients and Methods: Forty adult outpatients (between 18 to 55 years of age) with a diagnosis of MADD who met the trial criteria, entered this double-blind, randomized study. Subjects were assigned to receive either generic citalopram or Cipram® for 8 weeks. Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) were utilized to assess depression and anxiety at baseline, weeks 4 and 8 of the study. Statistical analysis was performed using SPSS 14.0.
Results: Twenty patients received citalopram (mean dosages of 22 mg/day during the first 4 weeks and 33 mg/day during weeks 4 to 8) and 20 received Cipram® (mean dosages of 22 mg/day during the first 4 weeks and 29 mg/day during weeks 4 to 8). Both treatments were noted to be effective in improving the symptoms of MADD at weeks 4 and 8. The mean differences of HAM-D and HAM-A between Citalopram and Cipram® groups were significantly different at the end of week 4 (HAM-D: P = 0.038, HAM-A: P = 0.025), but not at the end of week 8 (HAM-D: P = 0.239, HAM-A: P = 0.204). Both medications were tolerated well by the patients.
Conclusions: This study suggests that the efficacy of citalopram is similar to that of Cipram® in the treatment of MADD after 8 weeks. Meanwhile, Cipram® may reduce depression and anxiety quicker than its generic, citalopram.
